Abstract:Introduction: Silent information regulator 1 (SIRT1) has been extensively investigated in the cardiovascular system and has been shown to play a pivotal role in mediating cell death/survival, energy production, and oxidative stress. However, the functional role of SIRT1 in pressure overload-induced cardiac hypertrophy and dysfunction remains unclear. Resveratrol (Rsv), a widely used activator of SIRT1, has been reported to protect against cardiovascular disease. We here examine whether activation of SIRT1 by Rsv attenuate pressure overload-induced cardiac hypertrophy and to identify the underlying molecular mechanisms. Methods: In vivo, rat model of pressure overload-induced myocardial hypertrophy was established by abdominal aorta constriction (AAC) procedure. In vitro, Angiotensin II (Ang II) was applied to induce hypertrophy in cultured neonatal rat cardiomyocytes (NCMs). Hemodynamics and histological analyses of the heart were evaluated. The expression of SIRT1, transforming growth factor-β1 (TGF-β1)/phosphorylated (p)-small mother against decapentaplegic (Smad)3 and hypertrophic markers were determined by immunofluorescence, real-time PCR, and Western blotting techniques. Results: In the current study, Rsv treatment improved left ventricular function and reduced left ventricular hypertrophy and cardiac fibrosis significantly in the pressure overload rats. The expression of SIRT1 was significantly reduced, while the expression of TGF-β1/p-Smad3 was significantly enhanced in AAC afflicted rat heart. Strikingly, treatment with Rsv restored the expressions of SIRT1 and TGF-β1/p-Smad3 under AAC influence. However, SIRT1 inhibitor Sirtinol (Snl) markedly prevented the effects of Rsv, which suggest that SIRT1 signaling pathway was involved in the cardiac protective effect of Rsv. In vitro studies performed in Ang II-induced hypertrophy in NCMs confirmed the cardiac protective effect of Rsv. Furthermore, the study presented that SIRT1 negatively correlated with the cardiac hypertrophy, cardiac fibrosis, and the TGF-β1/p-Smad3 expression. Conclusions: Taken together, these results indicated that activation of SIRT1 by Rsv attenuates cardiac hypertrophy, cardiac fibrosis, and improves cardiac function possibly via regulation of the TGF-β1/p-Smad3 signaling pathway. Our study may provide a potential therapeutic strategy for cardiac hypertrophy.

STAT3 Suppression is Involved in the Protective Effect of SIRT6 Against Cardiomyocyte Hypertrophy.

SIRT6 Suppresses Mitochondrial Defects and Cell Death Via the NF-κB Pathway in Myocardial Hypoxia/reoxygenation Induced Injury.

SIRT6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p300.

SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy.

SIRT 6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p 300

Sirtuin 6 Protects Cardiomyocytes from Hypertrophy in Vitro Via Inhibition of NF‐κB‐dependent Transcriptional Activity

SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity

SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy

Sirt3 Attenuates Angii-Induced Cardiac Fibrosis by Inhibiting Myofibroblasts Transdifferentiation Via Stat3-Nfatc2 Pathway

SZC-6, a Small-Molecule Activator of SIRT3, Attenuates Cardiac Hypertrophy in Mice

SIRT3 improved peroxisomes-mitochondria interplay and prevented cardiac hypertrophy via preserving PEX5 expression

The Sirtuin 6 Prevents Angiotensin II-mediated Myocardial Fibrosis and Injury by Targeting AMPK-ACE2 Signaling

SIRT1 Functions As an Important Regulator of Estrogen-Mediated Cardiomyocyte Protection in Angiotensin II-Induced Heart Hypertrophy

SIRT3 Inhibits Ang II-induced Transdifferentiation of Cardiac Fibroblasts Through Β-Catenin/ppar-γ Signaling

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

Receptor‐interacting Protein 140 Represses Sirtuin 3 to Facilitate Hypertrophy, Mitochondrial Dysfunction and Energy Metabolic Dysfunction in Cardiomyocytes

The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun

NMNAT3 is Involved in the Protective Effect of SIRT3 in Ang II-induced Cardiac Hypertrophy

SIRT6 protects cardiomyocytes against ischemia/reperfusion injury by augmenting FoxO3α-dependent antioxidant defense mechanisms

Activation of SIRT1 by Resveratrol Alleviates Pressure Overload-Induced Cardiac Hypertrophy via Suppression of TGF-β1 Signaling

Mouse Sirt3 Promotes Autophagy in AngII-induced Myocardial Hypertrophy Through the Deacetylation of FoxO1.